# Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes

> **NCT01272219** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 3731 (actual)

## Conditions studied

- Metabolism and Nutrition Disorder
- Obesity

## Interventions

- **DRUG:** liraglutide
- **DRUG:** placebo
- **DRUG:** liraglutide
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01272219
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06-01
- **Primary completion:** 2013-03-18
- **Final completion:** 2015-03-02
- **Target enrollment:** 3731 (ACTUAL)
- **Last updated:** 2018-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01272219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01272219, "Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT01272219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*